Available EU DMF/CEP
EU DMF
CEP
API Status
Commercial
Pipeline
Therapeutic Category
Alimentary tract & metabolism
Anti-infectives for systemic use
Antipyretic, analgesic and anti-inflammatory
Antineoplastic & immunomodulating agents
Blood & blood forming organs
Cardiovascular system
Genito-urinary system & sex hormones
Injectable forms
Musculo-skeletal system
Nervous system
Opthalmological preparations
Respiratory system
Available US DMF
US DMF
Available Japanese/Chinese DMF
Japanese DMF
Chinese DMF
Korean DMF

Rivaroxaban

CAS No.

366789-02-8

Innovator/marketer

Xarelto

Polymorphic form

Modification I

Therapeutic Area

Blood & blood forming organs

Status

Pipeline

EU DMF readiness

US DMF readiness

027661

Other documentation

Chinese DMF

Drug description:

Rivaroxaban belongs to the class of antithrombotic agents. Rivaroxaban reduces a risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack. It is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
It is formulated as film-coated tablet and tablet for oral administration.

Mechanism of action:

Rivaroxaban is a factor Xa inhibitor. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombus. By blocking factor Xa, the level of thrombin decreases, which reduces the risk of blood clots forming in the veins and arteries, and also treats existing clots.

DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.

OK